Glenmark Pharma

{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,100.00",
    "chg": 12.7,
    "chgp": "0.61%",
    "dir": 1,
    "prev_price": "2,087.30",
    "mcapval": "59,942.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "Mar 24",
    "curr_time": "",
    "bse_nse_vol": "5.61 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 24, 2026",
    "traded_date_str": "2026 03 24",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3910785",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910785.png",
        "date": "2026-03-24 15:00:36",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 18.9% surge in open interest in its derivatives segment, signalling heightened market activity despite recent price underperformance. This spike in open interest, coupled with volume patterns and shifting investor positioning, suggests evolving directional bets on the mid-cap pharmaceutical player amid a cautious sector backdrop."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-market-signals-3910658",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910658.png",
        "date": "2026-03-24 14:00:31",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 23.15% surge in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of investor sentiment and technical factors."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Surge in Open Interest Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-surge-in-open-interest-amid-mixed-market-signals-3910533",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910533.png",
        "date": "2026-03-24 13:00:25",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 21.25% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.83% gain in the stock price, the underlying dynamics suggest a complex interplay of directional bets and liquidity flows within the mid-cap pharmaceutical sector."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3910397",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910397.png",
        "date": "2026-03-24 12:00:12",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 19.9% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock marginally underperformed its sector and broader indices, reflecting a complex interplay between bullish bets and cautious sentiment among traders."
      },
      {
        "title": "Why is Glenmark Pharmaceuticals Ltd. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glenmark-pharmaceuticals-ltd-fallingrising-3897834",
        "imagepath": "",
        "date": "2026-03-18 01:20:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Context</strong></p>\n<p>Despite the recent fall, Glenmark’s stock has demonstrated resilience over longer periods. The one-week return shows a decline of 4.05%, which is steeper than the Sensex’s 2.73% drop, indicating some short-term underperformance relative to the broader market. However, over the past month, the stock has gained 4.89%, contrasting with the Sensex’s 8.84% loss, and year-to-date it has risen by 5.01% while the benchmark index has declined by 10.74%. These figures suggest that while the stock faced pressure on 17-Mar, it remains a strong performer in a challenging market environment.</p>\n<p>On the day in question, Glenmark underperformed its sector by 2.01%, and the share price was trading below its five-day moving average, though it rem..."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-buy-3896250",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_mojoScore_3896250.png",
        "date": "2026-03-17 10:10:32",
        "description": "Glenmark Pharmaceuticals Ltd. is rated Buy by MarketsMOJO, with this rating last updated on 31 January 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Glenmark Pharmaceuticals Gains 2.25%: 3 Key Factors Driving the Week’s Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-gains-225-3-key-factors-driving-the-weeks-resilience-3891102",
        "imagepath": "",
        "date": "2026-03-14 13:04:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Mar 09:</strong> Stock opens at Rs.2,116.85 amid Sensex decline</p>\n                    <p><strong>Mar 10:</strong> Intraday high surge of 5.08% and surge in call option activity</p>\n                    <p><strong>Mar 11:</strong> New 52-week high at Rs.2,297.20</p>\n                    <p><strong>Mar 13:</strong> Week closes at Rs.2,170.00, down 3.90% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,122.15</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.2,170.00</div><d..."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Hits New 52-Week High at Rs 2297.2",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-new-52-week-high-at-rs-22972-3885212",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_priceRelatedfactors_3885212.png",
        "date": "2026-03-11 13:10:50",
        "description": "Glenmark Pharmaceuticals Ltd. has reached a significant milestone by hitting a new 52-week high of Rs 2297.2 on 11 Mar 2026, marking a notable achievement in its stock performance amid a challenging broader market environment."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Hits Intraday High with 5.08% Surge on 10 Mar 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-intraday-high-with-508-surge-on-10-mar-2026-3882982",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_priceRelatedfactors_3882982.png",
        "date": "2026-03-10 14:46:00",
        "description": "Glenmark Pharmaceuticals Ltd. demonstrated robust intraday strength on 10 Mar 2026, surging to an intraday high of Rs 2,225, marking a 5.11% increase from the previous close. This performance notably outpaced the broader Sensex, which gained a modest 0.67% during the session."
      }
    ],
    "total": 504,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) in India. Setting a new benchmark in affordability for GLP-1 therapy with weekly treatment starting at Rs. 325",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "19-Mar-2026",
      "details": "Glenmark Pharmaceuticals Inc. USA launches Authorised Generic to Milnacipran Hydrochloride Tablets 12.5 mg 25 mg 50 mg and 100 mg",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "19-Mar-2026",
      "details": "Glenmark Therapeutics Inc. USA launches Fluticasone Propionate Nasal Spray USP 50 mcg per spray (OTC)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-03-24 15:00:36

Glenmark Pharmaceuticals Ltd. has witnessed a significant 18.9% surge in open interest in its derivatives segment, signalling heightened market activity despite recent price underperformance. This spike in open interest, coupled with volume patterns and shifting investor positioning, suggests evolving directional bets on the mid-cap pharmaceutical player amid a cautious sector backdrop.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals

2026-03-24 14:00:31

Glenmark Pharmaceuticals Ltd. has witnessed a significant 23.15% surge in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of investor sentiment and technical factors.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Surge in Open Interest Amid Mixed Market Signals

2026-03-24 13:00:25

Glenmark Pharmaceuticals Ltd. has witnessed a significant 21.25% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.83% gain in the stock price, the underlying dynamics suggest a complex interplay of directional bets and liquidity flows within the mid-cap pharmaceutical sector.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-03-24 12:00:12

Glenmark Pharmaceuticals Ltd. has witnessed a notable 19.9% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock marginally underperformed its sector and broader indices, reflecting a complex interplay between bullish bets and cautious sentiment among traders.

Read full news article

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

2026-03-18 01:20:34

Short-Term Price Movement and Market Context

Despite the recent fall, Glenmark’s stock has demonstrated resilience over longer periods. The one-week return shows a decline of 4.05%, which is steeper than the Sensex’s 2.73% drop, indicating some short-term underperformance relative to the broader market. However, over the past month, the stock has gained 4.89%, contrasting with the Sensex’s 8.84% loss, and year-to-date it has risen by 5.01% while the benchmark index has declined by 10.74%. These figures suggest that while the stock faced pressure on 17-Mar, it remains a strong performer in a challenging market environment.

On the day in question, Glenmark underperformed its sector by 2.01%, and the share price was trading below its five-day moving average, though it rem...

Read full news article

Glenmark Pharmaceuticals Ltd. is Rated Buy

2026-03-17 10:10:32

Glenmark Pharmaceuticals Ltd. is rated Buy by MarketsMOJO, with this rating last updated on 31 January 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Read full news article

Glenmark Pharmaceuticals Gains 2.25%: 3 Key Factors Driving the Week’s Resilience

2026-03-14 13:04:20

Key Events This Week

Mar 09: Stock opens at Rs.2,116.85 amid Sensex decline

Mar 10: Intraday high surge of 5.08% and surge in call option activity

Mar 11: New 52-week high at Rs.2,297.20

Mar 13: Week closes at Rs.2,170.00, down 3.90% on the day

Week Open

Rs.2,122.15

Week Close

Rs.2,170.00

Read full news article

Glenmark Pharmaceuticals Ltd. Hits New 52-Week High at Rs 2297.2

2026-03-11 13:10:50

Glenmark Pharmaceuticals Ltd. has reached a significant milestone by hitting a new 52-week high of Rs 2297.2 on 11 Mar 2026, marking a notable achievement in its stock performance amid a challenging broader market environment.

Read full news article

Glenmark Pharmaceuticals Ltd. Hits Intraday High with 5.08% Surge on 10 Mar 2026

2026-03-10 14:46:00

Glenmark Pharmaceuticals Ltd. demonstrated robust intraday strength on 10 Mar 2026, surging to an intraday high of Rs 2,225, marking a 5.11% increase from the previous close. This performance notably outpaced the broader Sensex, which gained a modest 0.67% during the session.

Read full news article

View All News